Key Highlights
- Symvess sales rose 151% from the second quarter to slightly over USD 1 million in the third quarter ended September 30, 2026, management said, against USD 0.7 million in the third quarter of 2025.
- The net loss was USD 15.5 million, or USD 0.06 per share, versus USD 17.5 million, or USD 0.11, as Research and Development expense fell to USD 14.1 million from USD 17.3 million.
- The number of hospitals ordering Symvess rose 44% to 49 from 34 at the end of the second quarter, and October sales reached USD 800,000, according to the chief commercial officer.
- Cash, cash equivalents and restricted cash were USD 64.9 million, and the filing says Liquidity will not cover operations beyond one year without sufficient commercial Cash Flow or new capital.
Symvess Adoption Accelerates From a Small Base
Humacyte (NASDAQ:HUMA) filed its Quarterly Report and held its Earnings Call on November 10, 2026. Symvess commercial sales were USD 1.0 million, compared with USD 0.4 million in the second quarter, and the filing shows total Revenue of USD 1.03 million against USD 0.75 million a year earlier. Nine-month Symvess sales were USD 1.9 million versus USD 1.0 million. Management credited a rebuilt commercial team led by a chief commercial officer appointed in May, refined introductory pricing and incentive programs, and peer education. It expects fourth-quarter sales to at least double the third quarter and at least 20 new hospitals to order by year-end.
Lower Spending, Unused Capacity and the Earn-Out Gain
The company develops engineered human tissue products, with Symvess as its first commercial product. Cost of Goods Sold rose to USD 1.4 million from USD 0.3 million, of which USD 0.6 million related to units sold and USD 0.8 million to overhead from unused production capacity. General and administrative expense was USD 9.0 million versus USD 7.6 million, including USD 0.6 million tied to a Shareholder litigation settlement reserve. Other Net Income was USD 8.0 million, mainly a noncash remeasurement of a contingent earn-out liability, which cushioned the loss. Nine-month net loss was USD 70.0 million against USD 16.0 million, because the prior-year period had a USD 61.3 million other income gain.
Dialysis Filing, Coronary Study and the Going Concern Warning
Management said it plans to submit a supplemental Biologics license application in November for its engineered vessel in dialysis access, supported by three Phase III studies. It also opened a Phase IIa study of a coronary version for bypass surgery and is screening patients. Operating cash use was USD 15.0 million versus USD 23.9 million, after a May 2026 plan to cut about 45 jobs. The filing cites USD 64.5 million of cash and cash equivalents and substantial doubt about continuing as a going concern. Risks include slow hospital onboarding, regulatory timing and the need for new capital.
Where Things Stand
It is too early to say. Humacyte (NASDAQ:HUMA) more than doubled Symvess sales sequentially, grew hospital accounts to 49 and guided to at least double the third-quarter level in the fourth quarter, but the base is only about USD 1 million against a USD 15.5 million quarterly loss. Part of the improvement also came from a noncash earn-out gain. Next markers are the dialysis sBLA submission later in November, October-style monthly sales momentum, the coronary study enrolment and any financing, given the going concern language.




_11_13_2026_20_27_09_053340.jpg)

Please wait processing your request...